BRANDON WEINSTOCK: Open Payments
NPI 1396380705 · REDDING, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$970 in 41 payments from 8 companies in 2025. Trend: 2023 $1,289 · 2024 $1,084 · 2025 $970
Food & beverage: $970
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 13 | $315 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $208 |
| Neurocrine BioSciences, Inc. | 6 | $168 |
| Janssen Pharmaceuticals, Inc | 5 | $119 |
| ABBVIE INC. | 3 | $70 |
| Vanda Pharmaceuticals Inc. | 3 | $61 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
Products named: ARISTADA, CAPLYTA, INGREZZA, INVEGA SUSTENNA, VRAYLAR, FANAPT, COBENFY, Qelbree.
Industry payments across CA — which companies pay providers there.
